Many of us are ENZA resistant in the CRPC phase. In preclinical study in turns out that Trametinib + Enza has a profound effect on proliferation, especially with PTEN loss and PI3K mutations, the pCa is then very dependent on the MAPK signalling pathway. There is a clinical trial II open for new patients, anybody in here on this trial?
Trametinib MAPK inhibitor in ENZA-R p... - Advanced Prostate...
Trametinib MAPK inhibitor in ENZA-R pCA - very interesting
Read more about...
1 Reply
•
Thanks for sharing this. I'm sure I will be there at some point in the future.
Not what you're looking for?
You may also like...
VIROTHERAPY - very interesting!
r-tumor-in-36-hours/
From the second article:
\\"Clinical trials undertaken at the Mayo Clinic are...
Interesting statement regarding PCa
\\"Studies have shown that the prostate cancer we see clinically in men in their 50-60s likely...
Aromatase Inhibitors and PCa
using aromatase inhibitors (AIs) in the context of PCa. Note that Dr. Charles \\"Snuffy\\" Myers is...
Adaptive dosing: very promising results with Enzalutamide + Lutetium
urotoday.com/video-lectures/esmo-2023/video/3699-enza-p-trial-shows-promise-for-enzalutamide-lutetiu
5Alpha Reductase Inhibitors in advanced Pca
note also that they are frequently used IN advanced Pca.... Are they useful in lowering actual...
Related Posts
Interesting double blind study on Muscadine Grape Skin Extract and PCa
Anxiety after coming off Enzalutamide 
SM-88 (TYME) is an interesting treatment - a PCa trial seems in order
Very interesting article. Prostate cancer 'cured' by shocking prostate cancer with testosterone.
Very interesting and important. Hormone therapy failure prevented or reversed
